89bio publishes positive results from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) in nature medicine

– published data showed consistent and significant reductions in triglycerides, atherogenic lipoproteins and liver fat, and pegozafermin's favorable safety and tolerability profile –

ETNB Ratings Summary

ETNB Quant Ranking